Keywords: UK, NICE, SMC, Novartis, Afinitor, Tasigna, Bristol-Meyes Squibb, Sprycel, EliLilly, Alimta, Janssen Cilag, Stelara

UK’s NICE says “no” to Novartis’ Afinitor for advanced RCC and delays Sprycel and Tasigna; Scotland backs Alimta and Stelara

Article | 9 February 2010

In draft guidance, published today, the UK’s National Institute for Health and Clinical Excellence (NICE) says it has been unable to recommend Swiss drug major Novartis’ Afinitor (everolimus) for the second line treatment of advanced renal cell carcinoma.

This draft guidance is now available for public consultation. Enjoying this artcle? To continue reading you need to login, take a FREE trial or subscribe.

30 day FREE trial

Sign up in less than 60 seconds! No payment needed.

Want to read the full article?
Take a 30 day FREE Trial

Take a no obligations 30 day trial.
Only one trial per user. Find out more details

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in